Table 3.
Network comparison of different treatments for Dermatology Life Quality Index and Physician’s Global Assessment in psoriasis patients.
| PBO | AM | ANT | Anti-IL12/23 | Anti-IL17 | Anti-TNF-α | |
|---|---|---|---|---|---|---|
| Dermatology Life Quality Index | ||||||
| PBO | 1 | 3.34 (−18.48, 24.82) | 2.75 (−29.15, 34.17) | 13.75 (4.61, 23.03) | 7.59 (−13.44, 28.50) | 9.61 (1.15, 18.11) |
| AM | −3.34 (−24.82, 18.48) | 1 | −0.55 (−39.1, 37.58) | 10.44 (−12.65, 33.71) | 4.29 (−25.36, 33.83) | 6.25 (−14.6, 27.26) |
| ANT | −2.75 (−34.17, 29.15) | 0.55 (−37.58, 39.10) | 1 | 10.98 (−21.69, 44.20) | 4.80 (−33.03, 42.39) | 6.83 (−25.58, 39.77) |
| Anti-IL12/23 | −13.75 (−23.03, −4.61) | −10.44 (−33.71, 12.65) | −10.98 (−44.2, 21.69) | 1 | −6.15 (−29.1, 16.45) | −4.13 (−15.66, 7.49) |
| Anti-IL17 | −7.59 (−28.5, 13.44) | −4.29 (−33.83, 25.36) | −4.80 (−42.39, 33.03) | 6.15 (−16.45, 29.10) | 1 | 2.02 (−19.49, 23.74) |
| Anti-TNF-α | −9.61 (−18.11, −1.15) | −6.25 (−27.26, 14.60) | −6.83 (−39.77, 25.58) | 4.13 (−7.49, 15.66) | −2.02 (−23.74, 19.49) | 1 |
| Physician’s Global Assessment | ||||||
| PBO | 1 | 4.48 (1.25, 16.28) | 2.48 (1.14, 5.53) | 29.67 (16.78, 52.98) | 95.58 (38.09, 252.14) | 18.17 (10.80, 30.88) |
| AM | 0.22 (0.06, 0.80) | 1 | 0.55 (0.12, 2.51) | 6.62 (1.68, 25.79) | 21.54 (4.57, 101.49) | 4.06 (1.20, 13.60) |
| ANT | 0.40 (0.18, 0.88) | 1.80 (0.40, 8.17) | 1 | 11.94 (4.48, 31.82) | 38.86 (11.47, 134.29) | 7.32 (2.80, 18.73) |
| Anti-IL12/23 | 0.03 (0.02, 0.06) | 0.15 (0.04, 0.59) | 0.08 (0.03, 0.22) | 1 | 3.25 (1.21, 8.94) | 0.61 (0.32, 1.20) |
| Anti-IL17 | 0.01 (0.00, 0.03) | 0.05 (0.01, 0.22) | 0.03 (0.01, 0.09) | 0.31 (0.11, 0.83) | 1 | 0.19 (0.07, 0.52) |
| Anti-TNF-α | 0.06 (0.03, 0.09) | 0.25 (0.07, 0.84) | 0.14 (0.05, 0.36) | 1.63 (0.84, 3.16) | 5.31 (1.93, 14.88) | 1 |
Bold: data with statically significant difference, which is highlighted in the upper region of each outcome. AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.